Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Barclay Hedge Fund Index down 0.29% (est.) in August (+1.69% YTD), equity short bias and arbitrage strategies profitable

Tuesday, September 14, 2010
Opalesque Industry Update – Hedge funds slid 0.29% in August according to the Barclay Hedge Fund Index compiled by BarclayHedge.

“Global equity markets beat a retreat in August as the ‘fear trade’ returned with a vigor after having been smothered by increased risk appetite in July,” says Sol Waksman, founder and president of BarclayHedge.

“The fear trade is a product of investor nervousness and typically gives rise to selling of equities and purchases of US Treasury bonds.”

The Barclay Equity Long Bias Index lost 2.03% in August, Equity Long/Short was down 0.76%, while the Equity Market Neutral Index nearly held its ground with a 0.10% loss.

Globally, the Pacific Rim Equities Index lost 1.29%, European Equities were down 0.50%, and Emerging Markets slid 0.08%.

On the positive side, the Barclay Equity Short Bias Index rebounded from a 3.21% loss in July with a 2.49% August gain.

Arbitrage strategies also performed well this month. Convertible Arbitrage was up 1.70%, Merger Arbitrage gained 1.22%, and the Fixed Income Arbitrage Index rose 1.11%.

“The fear trade helped to drive up bond prices in August, and interest-rate sensitive strategies were positively impacted,” says Waksman.

“Merger Arbitrage did well as HP launched a bidding war for 3Par, Intel purchased McAfee, and BHP pursued a hostile bid for PotashCorp.”

The Barclay Fund of Funds Index lost 0.02% in August, and is down 0.81% for the year.

(press release)

Full performance table: Source

kb

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for